Identifying novel biomarkers and immune response profile correlating to clinical outcome in ovarian cancer patients treated with a T cell activating immune therapy

Cancer afflicts 1 in 8 people worldwide. Recent advancements in bench-to-bedside translational research has resulted in numerous effective treatments. However, a harsh reality still exists in that only ~20% of patients respond positively to treatment. Not all cancers are created equal, which has led to these clinical complexities undermining treatment options. It is our goal to understand the cellular and immune cell factors, which determine patient outcomes. By examining how cancer hides from our immune system, it will be possible to identify personalised treatment strategies for cancer patients.

Brennan Dirk
Faculty Supervisor: 
Andrew Makrigiannis
Nova Scotia
Partner University: